Precision Therapeutics (NSDQ:AIPT) CEO Carl Schwartz recently boosted his stake in the company by $1.37 million, including a $950,000 loan and the $50,000 purchase of 78,125 shares of the company’s common stock, representing a price of $0.64 per share. As part of the investment, detailed this week in an SEC filing, Schwartz also received additional […]
Precision Therapeutics Inc.
Precision Therapeutics finalizes Helomics buy, completes pivot to personalized medicine
Precision Therapeutics (NSDQ:AIPT) said yesterday it inked a definitive merger agreement with Helomics, completing the company’s plan to pivot towards artificial-intelligence powered personalized medicine. Minneapolis-based Precision Therapeutics inked a deal to acquire the remaining 75% equity stake in Helomics in April, after having purchased preferred stock in the company convertible into a 20% stake in January and converting […]
Precision Therapeutics to acquire Helomics
Precision Therapeutics (NSDQ:AIPT) said today it inked a letter of intent to acquire the remaining equity in Helomics, making it a wholly owned subsidiary. Minneapolis, Minn.-based Precision Therapeutics, which currently owns 25% of Helomics, said that it will acquire the remaining 75% equity stake in the company. Precision Therapeutics said it is hopeful that a new […]
Precision Therapeutics takes Helomics stake to 25%
Precision Therapeutics (NSDQ:AIPT), formerly known as Skyline Medical, said today it converted a previous $500,000 loan with Helomics into a 5% equity stake, bringing the company’s ownership in Helomics up to 25%. In January, Minneapolis, Minn.-based Precision Therapeutics purchased preferred stock in Pittsburgh, Penn.-based Helomics convertible into a 20% stake. Helomics developed and maintains the […]
Invuity prez & CEO Sawyer steps down, Flora in as interim | Personnel Moves – March 13, 2018
Invuity (NSDQ:IVTY) said late last week that its president and chief executive officer Philip Sawyer has resigned and will be replaced by board member Scott Flora on an interim basis. Flora has served as a member of the board since last November, and has held positions as prez, CEO and director of Omniguide. He has also held […]
Precision Therapeutics to launch new genomics product in 2011
Fresh off a $34 million Series D fundraise, Precision Therapeutics Inc. is planning to launch a “genomics” product sometime in 2011.
